Although the capability of DNA to form a variety of non-canonical (non-B) structures has long been recognized, the overall significance of these alternate conformations in biology has only recently become accepted en masse. In order to provide access to genome-wide locations of these classes of predicted structures, we have developed non-B DB, a database integrating annotations and analysis of non-B DNA-forming sequence motifs. The database provides the most complete list of alternative DNA structure predictions available, including Z-DNA motifs, quadruplex-forming motifs, inverted repeats, mirror repeats and direct repeats and their associated subsets of cruciforms, triplex and slipped structures, respectively. The database also contains motifs predicted to form static DNA bends, short tandem repeats and homo(purine•pyrimidine) tracts that have been associated with disease. The database has been built using the latest releases of the human, chimp, dog, macaque and mouse genomes, so that the results can be compared directly with other data sources. In order to make the data interpretable in a genomic context, features such as genes, single-nucleotide polymorphisms and repetitive elements (SINE, LINE, etc.) have also been incorporated. The database is accessed through query pages that produce results with links to the UCSC browser and a GBrowse-based genomic viewer. It is freely accessible at http://nonb.abcc.ncifcrf.gov.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3013731PMC
http://dx.doi.org/10.1093/nar/gkq1170DOI Listing

Publication Analysis

Top Keywords

non-b database
8
non-b dna-forming
8
non-b
5
motifs
5
database
5
database predicted
4
predicted non-b
4
dna-forming motifs
4
motifs mammalian
4
mammalian genomes
4

Similar Publications

Islatravir (ISL) is the first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTtI) with novel modes of action. Data on ISL resistance are currently limited, particularly to HIV-1 non-B subtypes. This study aimed to assess prevalent nucleos(t)ide reverse transcriptase inhibitor (NRTI)-resistant mutations in HIV-1 subtype C for their phenotypic resistance to ISL.

View Article and Find Full Text PDF

Efficacy and Safety of Bispecific T-Cell Engagers in Relapsed/Refractory Multiple Myeloma: A Real-World Data-Based Case-Controlled Study.

Transplant Cell Ther

November 2024

Catholic Research Network for Multiple Myeloma, Republic of Korea; Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

Although bispecific T-cell engager (BiTE) is a promising treatment for relapsed/refractory multiple myeloma (RRMM), it needs to be evaluated in a real-world setting. This study aimed to evaluate the efficacy and safety of BiTEs compared with a synthetic standard of care (SOC). From a multicenter registry database of 474 patients with RRMM who received third- or more advanced-line treatments between January 2021 and October 2023, 1:1 propensity score-matched BiTE cohort (n = 71) and SOC cohort (n = 71) were established.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate how otitis media with effusion (OME) progresses in children under 12 who do not have hearing loss.
  • Nineteen observational studies were analyzed, revealing that the resolution rates of OME varied widely over time, from 10% to 99% by 12 months, with significant differences based on the population and the criteria for resolution.
  • Although there was a trend of improved resolution and recurring cases over longer follow-up, the results did not show a consistent pattern, indicating that varied populations and definitions played a role.
View Article and Find Full Text PDF
Article Synopsis
  • Doravirine (DOR) is a new HIV treatment that works against some drug-resistant strains, but its effectiveness against non-B subtypes like HIV-1 subtype C is not fully understood.
  • The study used South African data to examine how certain known mutations associated with resistance affect DOR susceptibility, finding that mutations such as V106M and Y188L significantly reduce DOR effectiveness.
  • The research emphasizes the importance of genotypic drug resistance testing before starting DOR-based therapy, especially in patients with a history of efavirenz or nevirapine treatment failures.*
View Article and Find Full Text PDF

B-Corp certification is a fairly modern business phenomenon. Consequently, research on its relationship with key business strategy variables is still inconclusive, while longitudinal analyses of its link to financial performance are scarce. To determine whether business profit could be a robust argument to attract companies to assess and certify their social and environmental impact, in this research we explore the connection that exists between the B-Corp certification and corporate financial performance in the short-, medium- and long-term.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!